Pharmacist-involved collaborative care In the management of patients with diabetes

The effectiveness of pharmacist-involved collaborative care model in the management of patients with diabetes mellitus in Singapore

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN90211238

Enrollment

330

Registered

2015-11-06

Start date

2013-05-01

Completion date

Unknown

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes and other chronic comorbidities such as hypertension and dyslipidemia Nutritional, Metabolic, Endocrine

Interventions

Eligible patients will be randomized into the intervention or control arms: 1. Patients assigned to the intervention arm will receive active involvement of the pharmacist in drug optim

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 21 years and above 2. Diagnosed with type 2 diabetes 3. HbA1c = 7% 4. Uncontrolled co-morbidities such as hypertension (>130/80 mm Hg) and dyslipidemia (LDL > 2.6 mmol/L and TG > 2.3 mmol/L) 5. Characteristics of CAREPILLS (defined as Closer monitoring, Adherence problem, Resistance to drug therapy, Empowerment in patient’s own therapy, Polypharmacy, Insulin titration, Lack in drug knowledge, Lack in drug administration techniques and Switching of drugs)

Exclusion criteria

Exclusion criteria: 1. Diagnosed with type 1 diabetes 2. Unable to communicate independently

Design outcomes

Primary

Measure	Time frame
1. Glycated hemoglobin (HbA1c), 2. Systolic blood pressure (SBP), 3. Low-density lipoprotein (LDL), 4. Triglycerides (TG) Will be measured at baseline, three- and six-months 5. Incidence of minor and major hypoglycemia, 6. Appropriateness of aspirin and ACEI/ARB use, 7. Diabetes-related clinical visit and hospitalization 8. Morisky Medication Adherence Scale (MMAS), 9. Euro Quality of Life Five Dimensions (EQ-5D), 10. Audit of Diabetes-Dependent Quality of Life (ADDQoL), 11. Problem Areas in Diabetes (PAID), 12. Diabetes Treatment Satisfaction Questionnaires (DTSQ) 13. Direct and indirect costs Will be measured at baseline and six-months	—

Measure

Time frame

1. Glycated hemoglobin (HbA1c), 2. Systolic blood pressure (SBP), 3. Low-density lipoprotein (LDL), 4. Triglycerides (TG) Will be measured at baseline, three- and six-months 5. Incidence of minor and major hypoglycemia, 6. Appropriateness of aspirin and ACEI/ARB use, 7. Diabetes-related clinical visit and hospitalization 8. Morisky Medication Adherence Scale (MMAS), 9. Euro Quality of Life Five Dimensions (EQ-5D), 10. Audit of Diabetes-Dependent Quality of Life (ADDQoL), 11. Problem Areas in Diabetes (PAID), 12. Diabetes Treatment Satisfaction Questionnaires (DTSQ) 13. Direct and indirect costs Will be measured at baseline and six-months

—

Countries

Singapore

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026